PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34025070-16	2021	Moreover, SB203580 significantly reduced the pulmonary P-p38, NFkappaB, P-signal transducer and activator of transcription-3 and Myd88 levels but increased the IkappaB and HO-1 levels.	SB 203580	10-18	heme oxygenase 1	Homo sapiens	172-176	
34135317-11	2021	By contrast, downregulation of p38-MAPK by SB203580 decreased intracellular ROS level and enhanced the expression of HO-1.	SB 203580	43-51	heme oxygenase 1	Homo sapiens	117-121	
25341814-7	2014	The HO-1 activity and HO-1 expression level were significantly higher after atorvastatin treatment than before atorvastatin treatment and attenuated by SB203580 and PD98059 but not by SP600125, suggesting that the ERK and p38 mitogen-activated protein kinase (MAPK) pathways participate in regulating the above-mentioned effects of atorvastatin.	SB 203580	152-160	heme oxygenase 1	Homo sapiens	4-8	
29656184-8	2018	Blockage of p38 phosphorylation with its specific inhibitor SB203580 or by transfection with p38 siRNA restrained ropivacaine-stimulated HO-1 expression.	SB 203580	60-68	heme oxygenase 1	Homo sapiens	137-141	
29796178-4	2018	Induction of HO-1 protein expression was mimicked by SB203580, another p38 MAPK inhibitor, but not by SB202474, an inactive structural analogue of p38 MAPK inhibitors.	SB 203580	53-61	heme oxygenase 1	Homo sapiens	13-17	
29796178-5	2018	HO-1 induction by both SB202190 and SB203580 was also demonstrated by analysis of mRNA expression.	SB 203580	36-44	heme oxygenase 1	Homo sapiens	0-4	
25341814-7	2014	The HO-1 activity and HO-1 expression level were significantly higher after atorvastatin treatment than before atorvastatin treatment and attenuated by SB203580 and PD98059 but not by SP600125, suggesting that the ERK and p38 mitogen-activated protein kinase (MAPK) pathways participate in regulating the above-mentioned effects of atorvastatin.	SB 203580	152-160	heme oxygenase 1	Homo sapiens	22-26	
24932697-10	2014	We also demonstrated that the specific p38 MAPK inhibitor, SB203580, concentration-dependently blocked on gastrodin-induced HO-1 expression, and meanwhile SB203580 reversed the protective effect of gastrodin against MPP(+)-induced cell death.	SB 203580	59-67	heme oxygenase 1	Homo sapiens	124-128	
20515663-6	2010	The increase of HO-1 protein was suppressed by a p38 MAPK inhibitor SB203580, and early activation of p38 MAPK after thrombin treatment was observed in neurons and microglia in the striatum.	SB 203580	68-76	heme oxygenase 1	Homo sapiens	16-20	
23412940-6	2013	HO-1 expression was downregulated in cells treated with SB203580 and RAPA.	SB 203580	56-64	heme oxygenase 1	Homo sapiens	0-4	
23412940-7	2013	HO-1 overexpression inhibited apoptosis and induced G2/M arrest in SB203580 and RAPA-treated cells.	SB 203580	67-75	heme oxygenase 1	Homo sapiens	0-4	
23536693-4	2013	Specific inhibitors of mitogen-activated protein kinases (MAPKs), SB203580, PD98059, and SP600125, significantly abolished HO-1 expression.	SB 203580	66-74	heme oxygenase 1	Homo sapiens	123-127	
22137262-5	2012	Pretreatment of HAEC with SB203580 (p38 MAPK inhibitor) or siRNA knockdown of p38 MAPK completely blocked EGCG-stimulated induction of HO-1.	SB 203580	26-34	heme oxygenase 1	Homo sapiens	135-139	
15504750-9	2004	Ritonavir-induced HO-1 protein was suppressed by SB203580 or SB202190 and preceded by immediate upregulation of cellular c-Fos and c-Jun protein levels.	SB 203580	49-57	heme oxygenase 1	Homo sapiens	18-22	
19548360-5	2008	The increases in reactive species and HO-1 protein are inhibited by agonists of glucocorticoid receptors (GR), such as RU28362, prednisolone, and dexamethasone, as well as by N-acetyl-L-cysteine and SB203580 (a p38 inhibitor), suggesting a role of GR in NF-induced increases in reactive species and HO-1.	SB 203580	199-207	heme oxygenase 1	Homo sapiens	38-42	
17277740-12	2007	Inhibitors of the mitogen-activated protein kinase (p38MAPK; SB203580) and Jun N-terminal kinase (JNK; SP600125) pathways inhibited vitreous-induction of HO-1.	SB 203580	61-69	heme oxygenase 1	Homo sapiens	154-158	
16123320-10	2005	Pretreatment with SB203580, a p38 mitogen-activated protein kinase inhibitor, reduced ALA-induced HO-1 mRNA expression by 75% and inhibited ALA-induced Nrf2 binding to the HO-1 ARE.	SB 203580	18-26	heme oxygenase 1	Homo sapiens	98-102	
16123320-10	2005	Pretreatment with SB203580, a p38 mitogen-activated protein kinase inhibitor, reduced ALA-induced HO-1 mRNA expression by 75% and inhibited ALA-induced Nrf2 binding to the HO-1 ARE.	SB 203580	18-26	heme oxygenase 1	Homo sapiens	172-176	
12878207-7	2003	Pretreatment with N-acetylcysteine, PD 98059, and SB 203580 decreased HO-1 upregulation in spermine NONOate-treated cells.	SB 203580	50-59	heme oxygenase 1	Homo sapiens	70-74	
15158123-7	2004	In addition, the induction of COX-2 and HO-1 expression by TGD was prevented by pretreatment with NAC or SB203580, a p38 MAPK inhibitor.	SB 203580	105-113	heme oxygenase 1	Homo sapiens	40-44	
14731112-7	2004	Antioxidant N -acetylcysteine and SB203580, an antioxidant and inhibitor of p38 MAPK (mitogen-activated protein kinase), abolished MG132-inducible HO-1 expression.	SB 203580	34-42	heme oxygenase 1	Homo sapiens	147-151	
14647439-8	2004	The levels of HO-1 and p21 induced were significantly inhibited by p38 mitogen-activated protein kinase (p38 MAPK) inhibitor (SB203580) and extracellular-regulated kinase (ERK) inhibitor (PD098059).	SB 203580	126-134	heme oxygenase 1	Homo sapiens	14-18	
33808635-8	2021	Moreover, SB203580, a selective p38 inhibitor, reduced HO-1 mRNA expression and increased palmitate-induced oxidative stress in HepG2 cells.	SB 203580	10-18	heme oxygenase 1	Homo sapiens	55-59	
12376363-7	2002	A chemical inhibitor of p38 MAPK (SB-203580) abolished TGF-beta1-inducible HO-1 mRNA expression.	SB 203580	34-43	heme oxygenase 1	Homo sapiens	75-79	
12376363-8	2002	Both SB-203580 and expression of a dominant-negative mutant of p38 MAPK inhibited TGF-beta1-induced ho-1 gene activation, as assayed by luciferase activity of an ho-1 enhancer/luciferase fusion construct (pMHO1luc-33+SX2).	SB 203580	5-14	heme oxygenase 1	Homo sapiens	100-104	
11015442-8	2000	Specific inhibition of p38 MAPK activation by the pyridinyl imidazol SB203580 or through overexpression of a p38 MAPK dominant negative mutant abrogated the antiapoptotic effect of HO-1.	SB 203580	69-77	heme oxygenase 1	Homo sapiens	181-185	
10874044-6	2000	SB203580, an inhibitor of p38, diminishes cadmium-stimulated pE1-luc expression and HO-1 mRNA levels by up to 70-80%.	SB 203580	0-8	heme oxygenase 1	Homo sapiens	84-88	
10872747-5	2000	Pre-treatment of the cells with PD98059, a selective ERK pathway inhibitor, and SB203580, a p38 MAPK inhibitor, blocked the induction of HO-1 by the NO donor in a dose-dependent manner.	SB 203580	80-88	heme oxygenase 1	Homo sapiens	137-141